KYN

Kyntra Bio, Inc. Common Stock (KYNB) Q1 2026 Earnings

KYNB·Reported May 11, 2026·After market close

Kyntra Bio, Inc. Common Stock reported Q1 2026 revenue of $3.7M (+35.1% YoY), beat analyst consensus of $1.6M by $2.1M. Diluted EPS came in at $-3.74 (+6.5% YoY), missed the $-3.36 consensus by $0.38.

Revenue
$3.7Mbeat by $2.1M
Consensus: $1.6M
Diluted EPS
$-3.74missed by $0.38
Consensus: $-3.36
SEC

SEC Filings

Earnings release8-K · 0001193125-26-216731
Quarterly report10-Q · 0001193125-26-219374

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Kyntra Bio, Inc. Common Stock's Q1 2026 earnings report.

Kyntra Bio, Inc. Common Stock (KYNB) reported Q1 2026 earnings on May 11, 2026 after market close.

Kyntra Bio, Inc. Common Stock reported revenue of $3.7M and diluted EPS of $-3.74 for Q1 2026.

Revenue beat the consensus estimate of $1.6M by $2.1M. EPS missed the consensus estimate of $-3.36 by $0.38.

Compared to the same quarter a year prior, revenue grew 35.1% from $2.7M a year earlier and diluted EPS grew 6.5% from $-4.00.

You can read the 8-K earnings release (0001193125-26-216731) and the 10-Q periodic report (0001193125-26-219374) directly on SEC EDGAR. The filing index links above go to sec.gov.